Attention Deficit Disorder Affects Nearly 47 Million Children Worldwide
Attention deficit disorder affects nearly 47 million children worldwide. In 2021, nearly 47 million children and young people under the age of 20 were living with attention deficit hyperactivity disorder (ADHD) with or without hyperactivity worldwide. This disorder, characterized by persistent difficulties in concentrating, impulsivity, or excessive restlessness, represents a major public health issue. The figures reveal a global prevalence of 1.78%, meaning that approximately one in 56 children is affected.
Australia stands out as the country where this disorder is most prevalent, with a rate of 5.62%, closely followed by other regions such as Australasia. In contrast, some areas of Africa and Asia have significantly lower rates, often due to limited access to diagnostics and specialized care. The differences observed between countries are partly explained by varying cultural criteria in the perception of symptoms. In societies where expectations of children are stricter, behaviors associated with this disorder are more easily identified as problematic.
Boys are much more affected than girls, with a prevalence of 2.52% compared to 0.99%. This disparity is partly explained by the fact that boys often exhibit more visible symptoms, such as hyperactivity, which attract more attention from parents and teachers. In girls, the signs are more likely to go unnoticed, as they tend to internalize their difficulties more, such as daydreaming or organizational problems.
The total number of cases has increased by nearly 10% since 1990, but this rise is mainly due to global population growth. In reality, prevalence and incidence rates have slightly decreased, by 6% and 5.8% respectively. This suggests that the proportion of affected children remains stable, or even slightly decreasing, despite better detection in some countries.
This disorder also has a significant impact on quality of life. In 2021, it was responsible for the loss of nearly 575,000 healthy life years among young people under the age of 20. This figure includes years lived with functional limitations but does not include premature deaths, as the disorder is not directly linked to increased mortality. However, recent studies show that affected individuals have a higher risk of accidents or suicides, which could mean that the actual burden is underestimated.
Symptoms generally appear between the ages of 3 and 12, with a peak in diagnosis between 5 and 9 years old. The impact is strongest between 10 and 14 years old, a period when academic and social demands become more pressing. As they age, some children see their symptoms diminish, but many continue to face difficulties during adolescence, particularly due to self-esteem issues or social relationships.
More developed countries record higher prevalence rates. This does not necessarily mean that the disorder is more widespread there, but rather that healthcare systems are better equipped to detect it. In regions where resources are lacking, such as sub-Saharan Africa or parts of Asia, many cases go unnoticed. Families often have to travel long distances to access a specialist, and waiting lists can extend for several months, delaying treatment.
The causes of this disorder are multiple and involve a combination of genetic and environmental factors. However, there is no solid evidence to show that major biological differences exist between populations. The observed variations are more likely explained by differences in how symptoms are perceived and interpreted. For example, in cultures where restlessness is less tolerated, children are more likely to be referred for diagnosis.
Finally, although current figures provide a global overview, they may underestimate reality. The methods used to estimate prevalence partly rely on extrapolations, especially in countries where data is lacking. Additionally, the burden associated with this disorder does not account for related problems, such as anxiety, depression, or behavioral disorders, which often worsen the situation for affected children.
Attention deficit disorder affects nearly 47 million children worldwide. In 2021, nearly 47 million children and young people under the age of 20 were living with attention deficit hyperactivity disorder (ADHD) with or without hyperactivity worldwide. This disorder, characterized by persistent difficulties in concentrating, impulsivity, or excessive restlessness, represents a major public health issue. The figures reveal a global prevalence of 1.78%, meaning that approximately one in 56 children is affected.
Australia stands out as the country where this disorder is most prevalent, with a rate of 5.62%, closely followed by other regions such as Australasia. In contrast, some areas of Africa and Asia have significantly lower rates, often due to limited access to diagnostics and specialized care. The differences observed between countries are partly explained by varying cultural criteria in the perception of symptoms. In societies where expectations of children are stricter, behaviors associated with this disorder are more easily identified as problematic.
Boys are much more affected than girls, with a prevalence of 2.52% compared to 0.99%. This disparity is partly explained by the fact that boys often exhibit more visible symptoms, such as hyperactivity, which attract more attention from parents and teachers. In girls, the signs are more likely to go unnoticed, as they tend to internalize their difficulties more, such as daydreaming or organizational problems.
The total number of cases has increased by nearly 10% since 1990, but this rise is mainly due to global population growth. In reality, prevalence and incidence rates have slightly decreased, by 6% and 5.8% respectively. This suggests that the proportion of affected children remains stable, or even slightly decreasing, despite better detection in some countries.
This disorder also has a significant impact on quality of life. In 2021, it was responsible for the loss of nearly 575,000 healthy life years among young people under the age of 20. This figure includes years lived with functional limitations but does not include premature deaths, as the disorder is not directly linked to increased mortality. However, recent studies show that affected individuals have a higher risk of accidents or suicides, which could mean that the actual burden is underestimated.
Symptoms generally appear between the ages of 3 and 12, with a peak in diagnosis between 5 and 9 years old. The impact is strongest between 10 and 14 years old, a period when academic and social demands become more pressing. As they age, some children see their symptoms diminish, but many continue to face difficulties during adolescence, particularly due to self-esteem issues or social relationships.
More developed countries record higher prevalence rates. This does not necessarily mean that the disorder is more widespread there, but rather that healthcare systems are better equipped to detect it. In regions where resources are lacking, such as sub-Saharan Africa or parts of Asia, many cases go unnoticed. Families often have to travel long distances to access a specialist, and waiting lists can extend for several months, delaying treatment.
The causes of this disorder are multiple and involve a combination of genetic and environmental factors. However, there is no solid evidence to show that major biological differences exist between populations. The observed variations are more likely explained by differences in how symptoms are perceived and interpreted. For example, in cultures where restlessness is less tolerated, children are more likely to be referred for diagnosis.
Finally, although current figures provide a global overview, they may underestimate reality. The methods used to estimate prevalence partly rely on extrapolations, especially in countries where data is lacking. Additionally, the burden associated with this disorder does not account for related problems, such as anxiety, depression, or behavioral disorders, which often worsen the situation for affected children.
Media Sources
Reference Document
DOI: https://doi.org/10.1038/s41380-026-03683-4
Title: Incidence, prevalence, and global burden of attention-deficit/hyperactivity disorder from 1990 to 2021 across 204 countries in individuals under age 20: data, with critical appraisal, from the 2021 Global Burden of Disease study
Journal: Molecular Psychiatry
Publisher: Springer Science and Business Media LLC
Authors: Samuele Cortese; Min Seo Kim; Jong Hoon Han; Sarah Soyeon Oh; Dong Keon Yon; Jae II Shin; Marco Solmi